BioMérieux Stock: Institut Mérieux Strengthens Its Position by €83 Million in Two Sessions
BioMérieux stock edges up 0.14% to €71.15 at midday this Thursday, May 7, in a nearly flat SBF 120 (-0.1%). The stock is attempting to consolidate after a nearly 25% drop over three months. Against this backdrop, Institut Mérieux, the reference shareholder, has just strengthened its position in the capital by more than €83 million in two transactions.
The historic shareholder of the Lyon-based group conducted two close acquisitions on the market. On April 30, Institut Mérieux acquired 779,245 shares at a unit price of €69.99, totaling €54.54 million. On May 4, another transaction involved the repurchase of 404,367 shares at €71.96, adding an additional €29.10 million. These purchases came after the stock's decline following the annual target warning issued on April 23, which led to a 17% drop in one session and set a seven-year low at €68.05.
Technical Setup: RSI at 28, Price Recovery from Bollinger Lows
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
At €71.15, the stock remains far from its moving averages: the MM50 is at €89.10 and the MM200 at €105.74, representing a respective gap of 25% and 49% above the price. An RSI at 28 indicates a persistent oversold zone, following the post-publication drop on April 23. The price is moving in the lower part of the Bollinger bands, near the lower boundary at €61.25, and is attempting stabilization above the technical support identified at €68.25. One-month volatility has returned to 8.18%. Looking ahead, the financial calendar points to the publication of the semi-annual results 2026 on July 28, which will assess the trajectory after the lowering of annual targets announced at the end of April.
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
